Iben Spanggaard

1.2k citations

43 papers · 561 indexed · 1 hit paper · h-index 15

Impact in

Biotechnology top 10%
- Microbial Inactivation Methods
Oncology top 10%
- HER2/EGFR in Cancer Research
- Cancer Immunotherapy and Biomarkers

Papers in

Cancer Research 14
- Cancer Genomics and Diagnostics 13
Oncology 22
- HER2/EGFR in Cancer Research 5
- Colorectal Cancer Treatments and Studies 4

Co-authors: Kim Overvad Janne Bigaard Birthe Lykke Thomsen Anne Tjønneland Kristoffer Staal Rohrberg Ulrik Lassen Julie Gehl Morten Mau‐Sørensen
Journals: Annals of Oncology (8 papers)Journal of Clinical Oncology (6 papers)Acta Oncologica (3 papers)BMC Cancer (2 papers)Advanced Healthcare Materials (2 papers)
Partner nations: Denmark United States France

In The Last Decade

Iben Spanggaard

37 papers receiving 550 citations

Hit Papers

align trajectories log scale

Trastuzumab deruxtecan in patients with solid tumours harbouring specific activating HER2 mutations (DESTINY-PanTumor01): an international, phase 2 study 2024 · 43 citations

Peers

Countries citing papers authored by Iben Spanggaard

Since Specialization

Citations

This map shows the geographic impact of Iben Spanggaard's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Iben Spanggaard with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Iben Spanggaard more than expected).

Fields of papers citing papers by Iben Spanggaard

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Iben Spanggaard. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Iben Spanggaard. The network helps show where Iben Spanggaard may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Iben Spanggaard, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Iben Spanggaard Line = papers co-authored together Iben Spanggaard links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Copenhagen Prospective Personalized Oncology (CoPPO)—impact of comprehensive genomic profiling in more than 2000 patients in a phase I setting Annals of Oncology ·Otto Wappenschmitt, Martin Højgaard, Joanne Kite, Iben Spanggaard, Ulrik Lassen, Lary A. Robinson, А С Колпакова, Frederik Otzen Bagger, J. Márquez Rubio, Mohamed A Elsaied, Jane P. Hasselby, Eric Santoni‐Rugiu, Finn Cilius Nielsen, Christina W. Yde, Chaopeng Shen	2025	2
2	Trastuzumab deruxtecan in patients with solid tumours harbouring specific activating HER2 mutations (DESTINY-PanTumor01): an international, phase 2 study The Lancet Oncology ·Bob T. Li, Funda Meric‐Bernstam, Aditya Bardia, Yoichi Naito, Salvatore Siena, Javier León Ordaz, Ian Anderson, Giuseppe Curigliano, Maria J. de Miguel, Maitri Kalra, Do‐Youn Oh, Joon Oh Park, Sophie Postel‐Vinay, Sun Young Rha, Taroh Satoh, Iben Spanggaard, Flavia Michelini, Eric Leifere, Karime Kalil Machado, Cristina Saura, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown) Hit paper breakdown →	2024	43
3	Targeting HER2-mutant metastatic cervical cancer with neratinib: Final results from the phase 2 SUMMIT basket trial Gynecologic Oncology ·Claire F. Friedman, Anishka D'souza, Diana Bello Roufai, Anna V. Tinker, Maria J. de Miguel, Valentina Gambardella, Jonathan W. Goldman, Sherene Loi, Michelle Melisko, Ana Oaknin, Iben Spanggaard, Geoffrey I. Shapiro, Adam C. ElNaggar, Stefano Panni, Vignesh Ravichandran, 悟小貫, Tamara Didishvili, Lisa D. Eli, David B. Solit	2024	15
4	Open-label, dose-escalation FIGHT-101 study of pemigatinib combined with targeted therapy, chemotherapy, or immunotherapy in patients with advanced malignancies ESMO Open ·Mansoor N. Saleh, Minal Barve, Vivek Subbiah, Kyriakos P. Papadopoulos, Daniel Morgensztern, Niharika B. Mettu, Sameek Roychowdhury, Iben Spanggaard, M L Veronese, Chuan Tian, Ian M. Silverman, Martin Gutierrez	2024	4
5	Actionable alterations in glioblastoma: Insights from the implementation of genomic profiling as the standard of care from 2016 to 2023 Neuro-Oncology Practice ·Marlene Müller-Brandeck, Thomas Urup, Hans Skovgaard Poulsen, Kirsten Grunnet, Heinz A. Hoppe, Linea Cecilie Melchior, Karen Bonde Larsen, Martin Højgaard, Iben Spanggaard, Otto Wappenschmitt, Kristoffer Staal Rohrberg, Ulrik Lassen, Benedikte Hasselbalch, Amrullah Ahmad	2024	3
6	Cytokine release syndrome caused by antineoplastic treatment with CAR-T and T-cell engaging therapies Ugeskrift for Læger ·Valentyna Pechena, Caroline Hasselbalch Riley, Søren Lykke Petersen, Iben Spanggaard, Martin Hutchings, Kristoffer Staal Rohrberg, Martin Højgaard	2024	0
7	654O Efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients (pts) with solid tumors harboring specific HER2-activating mutations (HER2m): Primary results from the international phase II DESTINY-PanTumor01 (DPT-01) study Annals of Oncology ·Bob T. Li, Funda Meric‐Bernstam, Aditya Bardia, Yoichi Naito, Salvatore Siena, Philippe Aftimos, Ian C. Anderson, Giuseppe Curigliano, Maria J. de Miguel, Mamta Kalra, D-Y. Oh, Sangamesh Yankanchi, Sophie Postel‐Vinay, Sun Young Rha, Taroh Satoh, Iben Spanggaard, Flavia Michelini, Aaron Smith, S. I. Dimitrov, C. Saura Manich	2023	19
8	New pathogenic germline variants identified in mesothelioma Lung Cancer ·Otto Wappenschmitt, Birgitte Bertelsen, Karin Wadt, A. P. Oliver, Iben Spanggaard, Martin Højgaard, Jens Benn Sørensen, Jesper Ravn, Ulrik Lassen, Finn Cilius Nielsen, Kristoffer Staal Rohrberg, Christina W. Yde	2023	3
9	617 A Phase I study of a tumor-targeted, fibroblast activation protein (FAP)-CD40 agonist (RO7300490) in patients with advanced solid tumors SHILAP Revista de lepidopterología ·Ignacio Melero, (unknown), Iben Spanggaard, Dae Woo Lee, James Spicer, Fiona Thistlethwaite, Stefan N. Symeonides, Do‐Youn Oh, Antoine Hollebecque, Corinne Rusterholz, Soga Kohei, منجد محمد فوزي آل غرير, Nicole A. Kratochwil, Bernhard Reis, A. Maio, Tomas Punte, Víctor Moreno	2023	3
10	2321TiP TEMPLE: Thiopurine enhanced mutations for PD-1/ligand-1 efficacy: A phase Ib/II clinical trial Annals of Oncology ·Juliana Camila Rego Duarte, 滋若山, Iben Spanggaard, Kjeld Schmiegelow, Kristoffer Staal Rohrberg	2023	1
11	ProTarget: a Danish Nationwide Clinical Trial on Targeted Cancer Treatment based on genomic profiling – a national, phase 2, prospective, multi-drug, non-randomized, open-label basket trial BMC Cancer ·Guillermo Tapia Paniagua, Martin Højgaard, Kristoffer Staal Rohrberg, Iben Spanggaard, Britt Elmedal Laursen, Morten Ladekarl, Charlotte Aaquist Haslund, Laurine Bente Schram Harsløf, Otto Wappenschmitt, Julie Gehl, Lise Søndergaard, Rikke Løvendahl Eefsen, Karin Holmskov Hansen, Annette Raskov Kodahl, Lars Henrik Jensen, Marianne Ingerslev Holt, W. Kośniewski, Christina W. Yde, Lise Barlebo Ahlborn, Ulrik Lassen	2023	11
12	55P Potential benefits of extensive genomic analysis in patients with KRAS mutated solid tumors: Concurrent alterations and potential targets Annals of Oncology ·S. Dam Roy, Iben Spanggaard, 滋若山, Otto Wappenschmitt, Camilla Qvortrup, 栾雅文, Mohamed A Elsaied, Mohamed Oussama Bounab, Gro Linno Willemoe, Gabriel Valjan, Ulrik Lassen, Kristoffer Staal Rohrberg	2022	1
13	Modeling Metastatic Colonization in a Decellularized Organ Scaffold‐Based Perfusion Bioreactor Advanced Healthcare Materials ·Maria Rafaeva, Edward R. Horton, Barbara Tomasella, Chris D. Madsen, Raphael Reuten, А.С. ФЕДЯЕВ, Margaret Agee, T. Jensen, R. Taylor, V. L. McQueen, Rolf Krenzer, Sebastian R. Nielsen, Manja Idorn, Per thor Straten, Kristoffer Staal Rohrberg, Iben Spanggaard, Martin Højgaard, Ulrik Lassen, Janine T. Erler, Alejandro E. Mayorca‐Guiliani	2021	16
14	Immune Cell Profiling of Peripheral Blood as Signature for Response During Checkpoint Inhibition Across Cancer Types Frontiers in Oncology ·M Bavera, Morten Hansen, Iben Spanggaard, Kristoffer Staal Rohrberg, Sine Reker Hadrup, Ulrik Lassen, Inge Marie Svane	2021	26
15	Common phenotypic dynamics of tumor-infiltrating lymphocytes across different histologies upon checkpoint inhibition: impact on clinical outcome Cytotherapy ·M Bavera, Annie Borch, Morten Hansen, Arianna Draghi, Iben Spanggaard, Kristoffer Staal Rohrberg, Sine Reker Hadrup, Ulrik Lassen, Inge Marie Svane	2020	12
16	Copenhagen Prospective Personalized Oncology (CoPPO)—Clinical Utility of Using Molecular Profiling to Select Patients to Phase I Trials Clinical Cancer Research ·A. P. Oliver, Kristoffer Staal Rohrberg, A. I. Glushenko, Lise Barlebo Ahlborn, Ane Yde Schmidt, Iben Spanggaard, Jane P. Hasselby, Eric Santoni‐Rugiu, Christina W. Yde, Morten Mau‐Sørensen, Finn Cilius Nielsen, Ulrik Lassen	2018	59
17	Gene Electrotransfer of Plasmid Antiangiogenic Metargidin Peptide (AMEP) in Disseminated Melanoma: Safety and Efficacy Results of a Phase I First-in-Man Study PubMed ·Iben Spanggaard, Marko Snoj, Andréa Cavalcanti, Céline Bouquet, Gregor Serša, Caroline Robert, Maja Čemažar, Elisabeth Dam, B. Vasseur, P Attali, Lluis M. Mir, Julie Gehl	2013	53
18	Spatial Distribution of Transgenic Protein After Gene Electrotransfer to Porcine Muscle Human Gene Therapy Methods ·Iben Spanggaard, Thomas J. Corydon, Pernille Højman, Hanne Gissel, Frederik Dagnæs‐Hansen, Thomas G. Jensen, Julie Gehl	2012	6
19	Calcium Electrotransfer for Termination of Transgene Expression in Muscle Human Gene Therapy ·Pernille Højman, Iben Spanggaard, 教夫菅原, Julie Gehl, Hanne Gissel	2011	16
20	Self-Reported and Technician-Measured Waist Circumferences Differ in Middle-Aged Men and Women Journal of Nutrition ·Janne Bigaard, Iben Spanggaard, Birthe Lykke Thomsen, Kim Overvad, Anne Tjønneland	2005	88

About Iben Spanggaard

Iben Spanggaard is a scholar working on Cancer Research, Oncology, Biotechnology, Pulmonary and Respiratory Medicine and Immunology, having authored 43 papers that have together received 561 indexed citations. Recurring topics across this work include Cancer Genomics and Diagnostics (13 papers), Lung Cancer Treatments and Mutations (7 papers), Microbial Inactivation Methods (6 papers), Fibroblast Growth Factor Research (5 papers), HER2/EGFR in Cancer Research (5 papers), Gastric Cancer Management and Outcomes (4 papers), Viral Infectious Diseases and Gene Expression in Insects (4 papers) and Colorectal Cancer Treatments and Studies (4 papers). The work is most often cited by research in Biotechnology (78 citations), Oncology (239 citations), Cancer Research (124 citations), Pharmacy (20 citations) and Pulmonary and Respiratory Medicine (118 citations). Iben Spanggaard has collaborated with scholars based in Denmark, United States and France. Frequent co-authors include Kim Overvad, Janne Bigaard, Birthe Lykke Thomsen, Anne Tjønneland, Kristoffer Staal Rohrberg, Ulrik Lassen, Julie Gehl, Morten Mau‐Sørensen, Lise Barlebo Ahlborn and Christina W. Yde. Their work appears in journals such as Annals of Oncology, Journal of Clinical Oncology, Acta Oncologica, BMC Cancer and Advanced Healthcare Materials.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact